Toll Brothers
TOL
Meritage Homes
MTH
Taylor Morrison Home
TMHC
D.R. Horton
DHI
KB Home
KBH
US Stock MarketDetailed Quotes
CMRX Chimerix
- 3.490
- -0.170-4.64%
Close Jan 8 16:00 ET
- 3.520
- +0.030+0.86%
Post 18:48 ET
314.01MMarket Cap-3.71P/E (TTM)
3.600High3.395Low1.19MVolume3.600Open3.660Pre Close4.16MTurnover1.59%Turnover RatioLossP/E (Static)89.97MShares3.80052wk High2.31P/B262.09MFloat Cap0.75052wk Low--Dividend TTM75.10MShs Float58.040Historical High--Div YieldTTM5.60%Amplitude0.750Historical Low3.488Avg Price1Lot Size
About Chimerix Company
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
Company Profile
SymbolCMRX
Company NameChimerix
Listing DateApr 11, 2013
Issue Price14.00
Founded2000
CEOMr. Michael T. Andriole
MarketNASDAQ
Employees72
Fiscal Year Ends12-31
Address2505 Meridian Parkway,Suite 100
CityDurham
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27713
Phone1-919-806-1074
Websitehttp://www.chimerix.com
Company Executives
- Name
- Position
- Salary
- Michael T. Andriole
- Director, Chief Executive Officer and President
- 1.31M
- Michelle LaSpaluto
- Chief Financial Officer
- --
- Thomas J. Riga
- Chief Operating Officer and Chief Commercial Officer
- --
- Dr. Allen S. Melemed
- Chief Medical Officer
- 931.79K
- David Jakeman
- Vice President, Finance and Accounting and Principal Accounting Officer
- --
- Dr. Michael A. Alrutz,PhD
- Senior Vice President, General Counsel and Corporate Secretary
- 793.85K
- Michael Sherman
- Chairman of the Board
- 1.52M
- Marc D. Kozin
- Director
- --
- Fred A. Middleton
- Independent Director
- 119.52K
- Dr. Robert J. Meyer, M.D.
- Independent Director
- 117.02K
- Dr. Pratik S. Multani, M.D.
- Independent Director
- 104.52K
- Victoria Vakiener
- Independent Director
- 107.02K
- Martha J. Dei
- Lead Independent Director
- 144.52K
- Lisa Lynn Decker, PhD
- Independent Director
- 67.78K
- Patrick C. Machado, J.D.
- Independent Director
- 124.52K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
